Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, Medytox Negotiating Merger

NEW YORK (GenomeWeb) – CollabRx and Medytox Solutions today said that they have entered into a non-binding letter of intent to negotiate a merger between the firms.

In addition, Medytox is providing CollabRx with a loan so the San Francisco-based bioinformatics firm can continue to operate while the firms negotiate a potential deal.

The merger would unite CollabRx's cloud-based clinical decision support products, which are focused on genomics-based, precision medicine for cancer patients, with Medytox's variety of services for healthcare providers. Among the Palm Beach, Fla.-based firm's offerings are clinical lab services, electronic health records, lab information systems, and medical billing services.

The firms recently entered into a loan and security agreement, under which Medytox has agreed to provide CollabRx with up to approximately $2.4 million as the firms consider a merger. Thus far, CollabRx has borrowed $135,476 under the loan agreement. In addition, if CollabRx enters into a merger or other sales of its shares or assets with another party it would be obligated to pay Medytox a $1 million fee, the firms said in a statement.

CollabRx received a letter from Nasdaq earlier this week warning that the firm may be delisted from the exchange due to its falling short of an exchange rule that it maintain a minimum of $2.5 million in stockholders' equity.

CollabRx's shares were up around 7 percent at $.74 in early Thursday afternoon trade on the Nasdaq. Medytox shares were unchanged at $7.00 on the OTC Bulletin Board.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.